Last reviewed · How we verify

NCT03749512

NLCR in Prediction of the Grade of Lung Tumor.

Completed Last updated 21 November 2018
What this trial tests

trial testing Complete blood count in Lung Neoplasm in 400 participants. Completed in 16 November 2018.

Timeline
1 October 2014
Primary endpoint
15 October 2018
16 November 2018

Quick facts

Lead sponsorMedical University of Silesia
StatusCompleted
Study typeOBSERVATIONAL
Enrollment400
Start date1 October 2014
Primary completion15 October 2018
Estimated completion16 November 2018
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of Silesia

Who can join

18 and older, any sex, with Lung Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to assess whether the value of neutrophil-lymphocyte count ratio from the routine preoperative blood test may predict lung tumors' grading.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Complete blood count

Trials testing the same drug.

Other recruiting trials for Lung Neoplasm

Currently open trials in the same condition.

Other Medical University of Silesia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03749512.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing